Crescent Biopharma, Inc. (CBIO)
US — Healthcare Sector
Automate Your Wheel Strategy on CBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including CBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CBIO
- Rev/Share 0.0
- Book/Share 0.0361
- PB 330.9797
- Debt/Equity 0.0118
- CurrentRatio 9.2098
- ROIC -0.2981
- MktCap 166016116.0
- FreeCF/Share -7.1088
- PFCF -0.0061
- PE -1119.2165
- Debt/Assets 0.0104
- DivYield 0
- ROE -1.0339
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CBIO | Jefferies | -- | Buy | -- | $26 | Aug. 25, 2025 |
| Initiation | CBIO | H.C. Wainwright | -- | Buy | -- | $25 | Aug. 11, 2025 |
| Initiation | CBIO | Wedbush | -- | Outperform | -- | $27 | July 14, 2025 |
| Initiation | CBIO | Stifel | -- | Buy | -- | $28 | June 25, 2025 |
News
About Crescent Biopharma, Inc. (CBIO)
- IPO Date 2014-01-10
- Website https://crescentbiopharma.com
- Industry Biotechnology
- CEO Joshua T. Brumm
- Employees 33
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.